Verona Pharma plc (NASDAQ:VRNA) is Parkman Healthcare Partners LLC's 10th Largest Position

Parkman Healthcare Partners LLC boosted its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 5.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 626,452 shares of the company's stock after purchasing an additional 31,063 shares during the quarter. Verona Pharma makes up approximately 2.3% of Parkman Healthcare Partners LLC's holdings, making the stock its 10th biggest position. Parkman Healthcare Partners LLC owned 0.78% of Verona Pharma worth $18,023,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in VRNA. GAMMA Investing LLC boosted its stake in Verona Pharma by 70.6% during the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company's stock worth $38,000 after buying an additional 553 shares during the period. CWM LLC purchased a new position in shares of Verona Pharma during the 2nd quarter worth about $29,000. EMC Capital Management purchased a new position in shares of Verona Pharma during the 2nd quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock worth $75,000 after purchasing an additional 529 shares during the period. Finally, Diversify Advisory Services LLC purchased a new position in shares of Verona Pharma during the 3rd quarter worth about $169,000. 85.88% of the stock is currently owned by institutional investors.

Insider Activity at Verona Pharma

In other news, CEO David Zaccardelli sold 245,784 shares of the business's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92. Following the transaction, the chief executive officer now directly owns 15,004,920 shares in the company, valued at $65,721,549.60. The trade was a 1.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark W. Hahn sold 12,936 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $5.00, for a total value of $64,680.00. Following the transaction, the chief financial officer now owns 14,276,000 shares in the company, valued at approximately $71,380,000. This represents a 0.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,622,112 shares of company stock worth $7,383,768 in the last 90 days. Corporate insiders own 4.80% of the company's stock.

Verona Pharma Stock Up 3.1 %

Shares of NASDAQ:VRNA traded up $1.19 during trading hours on Wednesday, hitting $39.85. The company's stock had a trading volume of 1,682,427 shares, compared to its average volume of 938,035. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -20.14 and a beta of 0.46. The firm's fifty day moving average price is $35.03 and its 200 day moving average price is $25.79. Verona Pharma plc has a 52 week low of $11.39 and a 52 week high of $40.76.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). The business had revenue of $5.62 million for the quarter, compared to analyst estimates of $2.31 million. During the same quarter last year, the firm earned ($0.18) EPS. As a group, research analysts expect that Verona Pharma plc will post -2.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Truist Financial lifted their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. Wells Fargo & Company boosted their price objective on shares of Verona Pharma from $50.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. HC Wainwright boosted their price objective on shares of Verona Pharma from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Finally, Canaccord Genuity Group boosted their price objective on shares of Verona Pharma from $37.00 to $44.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $43.83.

Verona Pharma Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.